Pennsylvania HB1470 proposes a subscription model for GLP-1 agonists, medications used to treat obesity, through supplemental rebate agreements.

Pennsylvania HB1470 amends the Human Services Code to allow the state to enter into a subscription model for GLP-1 agonists, medications that mimic the effects of the GLP hormone on the body. The bill seeks a waiver from the Centers for Medicare and Medicaid Services to permit value-based arrangements with drug manufacturers through supplemental rebate agreements. These agreements would allow the state to pay an agreed amount per treatment up to a cap, after which treatments would be provided at no cost to the state.

Pennsylvania HB1470 proposes a subscription model for GLP-1 agonists, medications used to treat obesity, through supplemental rebate agreements.

Pennsylvania HB1470 amends the Human Services Code to allow the state to enter into a subscription model for GLP-1 agonists, medications that mimic the effects of the GLP hormone on the body. The bill seeks a waiver from the Centers for Medicare and Medicaid Services to permit value-based arrangements with drug manufacturers through supplemental rebate agreements. These agreements would allow the state to pay an agreed amount per treatment up to a cap, after which treatments would be provided at no cost to the state.